Treatments loaded in silicon nano-particles, 'bullet delivery' to cancer targets (NTERAPEUTICS)
Date
2023-06-15 17:15
Views
135
[The Way to Innovate Entrepreneurship] CEO Kang Jae-seung of Ntherapeutics
Kang Jae-seung, a professor at Seoul National University Medical School who founded Ntherapeutics, challenged the human barrier with a "silicon nano-particle drug delivery system (DDS)" technology that sends drugs to the target area. "It is important for the rocket to go up to the target orbit and inject the satellite, and the 'silicon nano-particles' effectively and safely take the drug to the target site like a rocket," said CEO Kang, who met at the Seoul National University's Yeon-geon Campus lab in Jong-no, Seoul on the 30th of last month.
The first areas where Ntherapeutics intends to apply silicon nano-particle technology are pancreatic cancer and brain tumors, which are difficult to treat. CEO Kang said, "The most difficult thing in chemotherapy is to break through the 'human body barrier' that prevents external substances from entering the body," adding, "There are effective pancreatic cancer and brain tumor treatments, but only a few drugs reach the target, and the rest spread to other places, causing side effects." Therefore, he said, "If you take more drugs than necessary, you will develop resistance."
However, the use of silicon nanoparticles enables effective drug delivery to the depths of the body. In other words, silicon, which has a low human rejection reaction, is split into very small nano-sized pieces enough to permeate the body, and then "bullet-delivery" is carried to target areas such as cancer and tumors. Existing drugs will also become new patents if they are placed on new drug delivery (DDS) platforms such as silicon nanoparticles. The company's goal is to use intravenous injections and oral transporters to easily administer drugs can be easily administered.
CEO Kang said, "We plan to expand the DDS platform so that we can load more various types of drugs by optimizing the loading rate for each drug type," adding, "We are currently working with Spinecker Bioscience in the U.S. and Adena in Belgium to commercialize it by obtaining approval from the U.S. Food and Drug Administration (EMA)."
Source: https://www.joongang.co.kr/article/25167126#home
Kang Jae-seung, a professor at Seoul National University Medical School who founded Ntherapeutics, challenged the human barrier with a "silicon nano-particle drug delivery system (DDS)" technology that sends drugs to the target area. "It is important for the rocket to go up to the target orbit and inject the satellite, and the 'silicon nano-particles' effectively and safely take the drug to the target site like a rocket," said CEO Kang, who met at the Seoul National University's Yeon-geon Campus lab in Jong-no, Seoul on the 30th of last month.
The first areas where Ntherapeutics intends to apply silicon nano-particle technology are pancreatic cancer and brain tumors, which are difficult to treat. CEO Kang said, "The most difficult thing in chemotherapy is to break through the 'human body barrier' that prevents external substances from entering the body," adding, "There are effective pancreatic cancer and brain tumor treatments, but only a few drugs reach the target, and the rest spread to other places, causing side effects." Therefore, he said, "If you take more drugs than necessary, you will develop resistance."
However, the use of silicon nanoparticles enables effective drug delivery to the depths of the body. In other words, silicon, which has a low human rejection reaction, is split into very small nano-sized pieces enough to permeate the body, and then "bullet-delivery" is carried to target areas such as cancer and tumors. Existing drugs will also become new patents if they are placed on new drug delivery (DDS) platforms such as silicon nanoparticles. The company's goal is to use intravenous injections and oral transporters to easily administer drugs can be easily administered.
CEO Kang said, "We plan to expand the DDS platform so that we can load more various types of drugs by optimizing the loading rate for each drug type," adding, "We are currently working with Spinecker Bioscience in the U.S. and Adena in Belgium to commercialize it by obtaining approval from the U.S. Food and Drug Administration (EMA)."
Source: https://www.joongang.co.kr/article/25167126#home